Xenon Pharmaceuticals Inc. (XENE) NASDAQ
$38.61 0.14 (0.36%)
Market Cap: $2.93B
As of 09/09/24 04:00 PM EDT. Market closed.
Xenon Pharmaceuticals Inc. (XENE)
NASDAQ
$38.61
0.14 (0.36%)
Market Cap: $2.93B
As of 09/09/24 04:00 PM EDT. Market closed.
Add to Portfolio
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Full Time Employees
251
CEO Compensation (Base)
$666,018
CEO Compensation (Total)
$10.12M
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Full Time Employees
251
CEO Compensation (Base)
$666,018
CEO Compensation (Total)
$10.12M
Address
3650 Gilmore Way, BC, Burnaby, V5G 4W8.
PRICE CHART FOR XENON PHARMACEUTICALS INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$38.72
Previous Close
$38.47
Days Range
$38.50 - $39.35
52 week range
$27.99 - $50.99
Volume
266,906
Avg. Volume (30 days)
402,409
Market Cap
$2.93B
Dividend Yield
-
P/E
(14.14)
Shares Outstanding
75,764,500
Open
$38.72
Previous Close
$38.47
Days Range
$38.50 - $39.35
52 week range
$27.99 - $50.99
Volume
266,906
Avg. Volume (30 days)
402,409
Market Cap
$2.93B
Dividend Yield
-
P/E
(14.14)
Shares Outstanding
75,764,500
FINANCIAL STATEMENTS FOR XENON PHARMACEUTICALS INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR XENON PHARMACEUTICALS INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| GAROFALO ELIZABETH A. | Director | Mar 08, 2024 | Option Exercise | $46.16 | 1,408 | 64,993 | 2,092 | Mar 11, 2024, 08:09 PM |
| GAROFALO ELIZABETH A. | Director | Mar 08, 2024 | Option Exercise | $18.56 | 3,500 | 64,960 | 3,500 | Mar 11, 2024, 08:09 PM |
| GAROFALO ELIZABETH A. | Director | Mar 08, 2024 | Sale | $45.69 | 2,092 | 95,583 | 0 | Mar 11, 2024, 08:09 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 07, 2024 | Option Exercise | $45.96 | 1,504 | 69,124 | 15,535 | Mar 08, 2024, 05:31 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 07, 2024 | Option Exercise | $9.85 | 8,641 | 85,114 | 16,824 | Mar 08, 2024, 05:31 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 07, 2024 | Sale | $46.28 | 7,137 | 330,290 | 14,516 | Mar 08, 2024, 05:31 PM |
| GANNON STEVEN | Director | Mar 07, 2024 | Sale | $46.28 | 13,000 | 601,615 | 14,000 | Mar 08, 2024, 05:28 PM |
| AZAB MOHAMMAD | Director | Dec 19, 2023 | Option Exercise | $9.85 | 4,320 | 42,552 | 74,225 | Dec 20, 2023, 05:04 PM |
| PATOU GARY | Director | Dec 14, 2023 | Sale | $41.05 | 7,598 | 311,898 | 4,902 | Dec 15, 2023, 09:50 PM |
| PATOU GARY | Director | Dec 13, 2023 | Option Exercise | $39.68 | 3,022 | 119,913 | 28,673 | Dec 15, 2023, 05:38 PM |
| PATOU GARY | Director | Dec 13, 2023 | Option Exercise | $9.55 | 14,402 | 137,487 | 29,951 | Dec 15, 2023, 05:38 PM |
| PATOU GARY | Director | Dec 13, 2023 | Sale | $41.05 | 7,598 | 311,898 | 4,902 | Dec 15, 2023, 05:38 PM |
| PATOU GARY | Director | Dec 13, 2023 | Sale | $39.29 | 11,380 | 447,085 | 23,573 | Dec 15, 2023, 05:38 PM |
| Svoronos Dawn | Director | Aug 24, 2023 | Sale | $38.70 | 25,000 | 967,500 | 25,000 | Aug 24, 2023, 04:33 PM |
| PIMSTONE SIMON N. | Director | Jun 01, 2023 | Option Exercise | $38.53 | 22,605 | 870,971 | 30,255 | Jun 01, 2023, 07:25 PM |
| PIMSTONE SIMON N. | Director | May 31, 2023 | Option Exercise | $38.37 | 29,309 | 1,124,586 | 32,856 | Jun 01, 2023, 07:25 PM |
| PIMSTONE SIMON N. | Director | May 31, 2023 | Option Exercise | $14.80 | 79,835 | 1,181,875 | 56,000 | Jun 01, 2023, 07:25 PM |
| PIMSTONE SIMON N. | Director | Jun 01, 2023 | Option Exercise | $16.03 | 54,318 | 870,855 | 51,000 | Jun 01, 2023, 07:25 PM |
| PIMSTONE SIMON N. | Director | May 31, 2023 | Sale | $38.70 | 62,526 | 2,420,051 | 6,000 | Jun 01, 2023, 07:25 PM |
| PIMSTONE SIMON N. | Director | May 30, 2023 | Sale | $39.28 | 37,006 | 1,453,672 | 37,000 | Jun 01, 2023, 07:25 PM |
| PIMSTONE SIMON N. | Director | Jun 01, 2023 | Sale | $38.82 | 31,713 | 1,231,247 | 6,000 | Jun 01, 2023, 07:25 PM |
| MORTIMER IAN | PRESIDENT & CEO | May 24, 2023 | Option Exercise | $41.84 | 12,383 | 518,105 | 41,282 | May 26, 2023, 07:10 PM |
| MORTIMER IAN | PRESIDENT & CEO | May 24, 2023 | Option Exercise | $9.60 | 69,340 | 665,536 | 48,592 | May 26, 2023, 07:10 PM |
| MORTIMER IAN | PRESIDENT & CEO | May 24, 2023 | Sale | $41.41 | 31,655 | 1,310,931 | 31,302 | May 26, 2023, 07:10 PM |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Mar 24, 2023 | Sale | $35.01 | 700 | 24,507 | 0 | Mar 24, 2023, 07:18 PM |
| PIMSTONE SIMON N. | Director | Mar 07, 2023 | Option Exercise | $37.13 | 3,778 | 140,277 | 63,248 | Mar 09, 2023, 06:21 PM |
| PIMSTONE SIMON N. | Director | Mar 07, 2023 | Option Exercise | $2.64 | 72,016 | 190,225 | 64,866 | Mar 09, 2023, 06:21 PM |
| PIMSTONE SIMON N. | Director | Mar 07, 2023 | Sale | $36.98 | 19,232 | 711,199 | 55,006 | Mar 09, 2023, 06:21 PM |
| AZAB MOHAMMAD | Director | Dec 12, 2022 | Option Exercise | $2.68 | 3,086 | 8,270 | 69,905 | Dec 13, 2022, 04:29 PM |
| PATOU GARY | Director | Nov 25, 2022 | Option Exercise | $34.37 | 120 | 4,124 | 25,510 | Nov 28, 2022, 08:41 PM |
| PATOU GARY | Director | Nov 25, 2022 | Option Exercise | $2.68 | 2,057 | 5,513 | 25,630 | Nov 28, 2022, 08:41 PM |
| PATOU GARY | Director | Nov 23, 2022 | Sale | $34.33 | 2,057 | 70,610 | 23,573 | Nov 28, 2022, 08:41 PM |
| PATOU GARY | Director | Nov 25, 2022 | Sale | $34.79 | 1,937 | 67,390 | 23,573 | Nov 28, 2022, 08:41 PM |
| AULIN SHERRY | Chief Financial Officer | Sep 02, 2022 | Option Exercise | $39.53 | 3,293 | 130,172 | 15,355 | Sep 07, 2022, 04:26 PM |
| AULIN SHERRY | Chief Financial Officer | Sep 02, 2022 | Option Exercise | $6.97 | 18,648 | 130,061 | 18,648 | Sep 07, 2022, 04:26 PM |
| AULIN SHERRY | Chief Financial Officer | Sep 02, 2022 | Sale | $39.57 | 15,355 | 607,597 | 0 | Sep 07, 2022, 04:26 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 01, 2022 | Option Exercise | $38.81 | 6,121 | 237,556 | 60,675 | Sep 02, 2022, 04:27 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Aug 31, 2022 | Option Exercise | $37.86 | 1,572 | 59,516 | 38,148 | Sep 02, 2022, 04:27 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 01, 2022 | Option Exercise | $4.75 | 50,000 | 237,500 | 66,796 | Sep 02, 2022, 04:27 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Aug 31, 2022 | Option Exercise | $3.13 | 22,488 | 70,443 | 39,720 | Sep 02, 2022, 04:27 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Aug 31, 2022 | Sale | $38.57 | 21,352 | 823,547 | 16,796 | Sep 02, 2022, 04:27 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 01, 2022 | Sale | $38.18 | 43,879 | 1,675,476 | 25,572 | Sep 02, 2022, 04:27 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Aug 12, 2022 | Option Exercise | $38.02 | 7,257 | 275,911 | 67,743 | Aug 16, 2022, 05:36 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Aug 12, 2022 | Option Exercise | $4.24 | 65,000 | 275,750 | 75,000 | Aug 16, 2022, 05:36 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Aug 12, 2022 | Sale | $38.31 | 57,743 | 2,211,979 | 31,875 | Aug 16, 2022, 05:36 PM |
| PIMSTONE SIMON N. | Director | Aug 16, 2022 | Sale | $38.51 | 52,058 | 2,004,901 | 26,000 | Aug 16, 2022, 05:31 PM |
| PIMSTONE SIMON N. | Director | Aug 15, 2022 | Sale | $37.76 | 33,942 | 1,281,650 | 58,058 | Aug 16, 2022, 05:31 PM |
| PIMSTONE SIMON N. | Director | Aug 12, 2022 | Sale | $38.28 | 91,135 | 3,488,598 | 140,000 | Aug 16, 2022, 05:31 PM |
| PIMSTONE SIMON N. | Director | Mar 08, 2022 | Sale | $30.80 | 2,500 | 77,000 | 193,135 | Mar 08, 2022, 09:41 PM |
| PIMSTONE SIMON N. | Director | Mar 07, 2022 | Option Exercise | $30.23 | 1,990 | 60,158 | 228,772 | Mar 08, 2022, 07:58 PM |
| PIMSTONE SIMON N. | Director | Mar 04, 2022 | Option Exercise | $31.42 | 963 | 30,257 | 219,511 | Mar 08, 2022, 07:58 PM |
| PIMSTONE SIMON N. | Director | Mar 07, 2022 | Option Exercise | $3.67 | 20,576 | 75,514 | 230,762 | Mar 08, 2022, 07:58 PM |
| PIMSTONE SIMON N. | Director | Mar 04, 2022 | Option Exercise | $3.67 | 10,288 | 37,757 | 220,474 | Mar 08, 2022, 07:58 PM |
| PIMSTONE SIMON N. | Director | Mar 07, 2022 | Sale | $30.50 | 31,086 | 948,260 | 223,735 | Mar 08, 2022, 07:58 PM |
| PIMSTONE SIMON N. | Director | Mar 04, 2022 | Sale | $30.61 | 9,325 | 285,425 | 214,979 | Mar 08, 2022, 07:58 PM |
| PIMSTONE SIMON N. | Director | Mar 08, 2022 | Sale | $25.82 | 14,551 | 375,636 | 195,635 | Mar 08, 2022, 07:58 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 04, 2022 | Option Exercise | $31.42 | 696 | 21,868 | 32,770 | Mar 08, 2022, 07:35 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 04, 2022 | Option Exercise | $3.67 | 7,406 | 27,180 | 38,942 | Mar 08, 2022, 07:35 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Mar 04, 2022 | Sale | $30.50 | 21,710 | 662,208 | 32,232 | Mar 08, 2022, 07:35 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 04, 2022 | Option Exercise | $31.42 | 6,685 | 210,043 | 28,315 | Mar 08, 2022, 07:32 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 07, 2022 | Option Exercise | $30.23 | 9,647 | 291,629 | 42,853 | Mar 08, 2022, 07:32 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 04, 2022 | Option Exercise | $8.40 | 25,000 | 210,000 | 35,000 | Mar 08, 2022, 07:32 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 07, 2022 | Option Exercise | $6.86 | 42,500 | 291,400 | 51,805 | Mar 08, 2022, 07:32 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 07, 2022 | Sale | $30.54 | 32,853 | 1,003,475 | 41,048 | Mar 08, 2022, 07:32 PM |
| EMPFIELD JAMES R. | EVP, Drug Discovery | Mar 04, 2022 | Sale | $30.79 | 18,315 | 563,919 | 10,000 | Mar 08, 2022, 07:32 PM |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Jan 21, 2022 | Buy | $28.81 | 700 | 20,167 | 700 | Jan 21, 2022, 05:04 PM |
| AZAB MOHAMMAD | Director | Dec 15, 2021 | Option Exercise | $3.67 | 3,086 | 11,326 | 66,819 | Dec 17, 2021, 04:04 PM |
| PATOU GARY | Director | Dec 08, 2021 | Option Exercise | $3.67 | 2,057 | 7,549 | 25,630 | Dec 10, 2021, 04:20 PM |
| Von Seggern Christopher | Chief Commercial Officer | Dec 06, 2021 | Buy | $24.40 | 4,000 | 97,600 | 4,000 | Dec 07, 2021, 04:13 PM |
| PIMSTONE SIMON N. | Director | Nov 15, 2021 | Sale | $31.33 | 17,557 | 550,061 | 210,186 | Nov 16, 2021, 08:40 PM |
| PATOU GARY | Director | Mar 17, 2021 | Option Exercise | $19.49 | 100 | 1,949 | 100 | Jun 04, 2021, 07:20 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | May 28, 2021 | Option Exercise | $18.91 | 4,216 | 79,725 | 38,299 | Jun 01, 2021, 04:11 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | May 28, 2021 | Option Exercise | $3.81 | 25,719 | 97,907 | 40,491 | Jun 01, 2021, 04:11 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | May 28, 2021 | Sale | $18.81 | 6,067 | 114,120 | 35,144 | Jun 01, 2021, 04:11 PM |
| PIMSTONE SIMON N. | CEO | May 24, 2021 | Option Exercise | $19.17 | 5,076 | 97,307 | 227,743 | May 26, 2021, 04:11 PM |
| PIMSTONE SIMON N. | CEO | May 24, 2021 | Option Exercise | $3.76 | 22,633 | 85,100 | 232,819 | May 26, 2021, 04:11 PM |
| Hayden Michael R | Director | Feb 16, 2021 | Option Exercise | $2.68 | 5,144 | 13,786 | 112,706 | Feb 18, 2021, 05:59 PM |
| Hayden Michael R | Director | Feb 18, 2021 | Option Exercise | $2.93 | 41,152 | 120,472 | 92,076 | Feb 18, 2021, 05:59 PM |
| AZAB MOHAMMAD | Director | Dec 15, 2020 | Option Exercise | $3.76 | 3,086 | 11,603 | 63,733 | Dec 15, 2020, 04:39 PM |
| TARNOW MICHAEL M | Director | Oct 28, 2020 | Option Exercise | $3.76 | 10,288 | 38,683 | 80,001 | Oct 29, 2020, 04:27 PM |
| PATOU GARY | Director | Oct 28, 2020 | Option Exercise | $3.76 | 2,057 | 7,734 | 23,573 | Oct 29, 2020, 04:20 PM |
| TARNOW MICHAEL M | Director | Jun 09, 2020 | Option Exercise | $3.52 | 5,144 | 18,107 | 69,713 | Jun 10, 2020, 05:17 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Jun 01, 2020 | Option Exercise | $13.70 | 1,630 | 22,331 | 16,796 | Jun 02, 2020, 05:40 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Jun 01, 2020 | Option Exercise | $3.56 | 8,230 | 29,299 | 18,426 | Jun 02, 2020, 05:40 PM |
| HOLLER FRANK A | Director | May 29, 2020 | Option Exercise | $3.56 | 3,086 | 10,986 | 122,041 | Jun 02, 2020, 04:54 PM |
| PIMSTONE SIMON N. | CEO | Jun 01, 2020 | Sale | $14.43 | 3,000 | 43,290 | 255,186 | Jun 02, 2020, 04:50 PM |
| PIMSTONE SIMON N. | CEO | May 29, 2020 | Sale | $13.99 | 5,000 | 69,950 | 258,186 | Jun 02, 2020, 04:50 PM |
| PIMSTONE SIMON N. | CEO | May 26, 2020 | Option Exercise | $14.90 | 1,108 | 16,509 | 263,186 | May 28, 2020, 05:02 PM |
| PIMSTONE SIMON N. | CEO | May 26, 2020 | Option Exercise | $3.56 | 6,172 | 21,972 | 264,294 | May 28, 2020, 05:02 PM |
| AZAB MOHAMMAD | Director | Dec 16, 2019 | Option Exercise | $3.56 | 3,086 | 10,986 | 60,647 | Dec 17, 2019, 05:04 PM |
| PATOU GARY | Director | Dec 04, 2019 | Option Exercise | $3.56 | 2,057 | 7,323 | 21,516 | Dec 06, 2019, 05:12 PM |
| TARNOW MICHAEL M | Director | Nov 21, 2019 | Option Exercise | $3.55 | 7,201 | 25,533 | 69,713 | Nov 22, 2019, 01:30 PM |
| PIMSTONE SIMON N. | CEO | Sep 20, 2019 | Sale | $9.51 | 10,395 | 98,856 | 258,122 | Sep 24, 2019, 06:14 PM |
| HOLLER FRANK A | Director | Sep 20, 2019 | Sale | $9.39 | 5,206 | 48,884 | 118,955 | Sep 20, 2019, 04:15 PM |
| HOLLER FRANK A | Director | Sep 19, 2019 | Sale | $9.27 | 7,600 | 70,452 | 124,161 | Sep 20, 2019, 04:15 PM |
| PIMSTONE SIMON N. | CEO | Sep 17, 2019 | Option Exercise | $9.44 | 17,230 | 162,651 | 268,517 | Sep 18, 2019, 07:06 PM |
| PIMSTONE SIMON N. | CEO | Sep 17, 2019 | Option Exercise | $3.53 | 57,612 | 203,381 | 272,209 | Sep 18, 2019, 07:06 PM |
| HOLLER FRANK A | Director | Sep 18, 2019 | Sale | $9.28 | 4,368 | 40,535 | 131,761 | Sep 18, 2019, 06:43 PM |
| HOLLER FRANK A | Director | Sep 17, 2019 | Sale | $9.32 | 5,069 | 47,243 | 136,129 | Sep 18, 2019, 06:43 PM |
| AZAB MOHAMMAD | Director | Sep 13, 2019 | Sale | $9.31 | 23 | 214 | 57,561 | Sep 17, 2019, 04:46 PM |
| HOLLER FRANK A | Director | Sep 12, 2019 | Option Exercise | $9.38 | 9,649 | 90,508 | 141,198 | Sep 13, 2019, 08:13 PM |
| HOLLER FRANK A | Director | Sep 12, 2019 | Option Exercise | $3.07 | 31,892 | 98,052 | 148,979 | Sep 13, 2019, 08:13 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 12, 2019 | Option Exercise | $9.38 | 1,868 | 17,522 | 10,196 | Sep 13, 2019, 06:58 PM |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | Sep 12, 2019 | Option Exercise | $3.07 | 6,172 | 18,948 | 12,064 | Sep 13, 2019, 06:58 PM |
| TARNOW MICHAEL M | Director | May 21, 2019 | Option Exercise | $3.21 | 2,057 | 6,603 | 64,569 | May 23, 2019, 11:56 AM |
| Hayden Michael R | Director | Mar 19, 2019 | Option Exercise | $3.38 | 20,576 | 69,547 | 50,924 | Mar 20, 2019, 05:13 PM |
| PATOU GARY | Director | Dec 14, 2018 | Option Exercise | $3.07 | 2,057 | 6,315 | 19,459 | Dec 18, 2018, 04:06 PM |
| COHEN CHARLES J. | VP, Biology | Dec 11, 2018 | Option Exercise | $7.00 | 1,644 | 11,508 | 6,550 | Dec 13, 2018, 01:56 PM |
| COHEN CHARLES J. | VP, Biology | Dec 11, 2018 | Option Exercise | $3.07 | 4,115 | 12,633 | 8,194 | Dec 13, 2018, 01:56 PM |
| AZAB MOHAMMAD | Director | Dec 06, 2018 | Option Exercise | $3.07 | 3,086 | 9,474 | 57,584 | Dec 10, 2018, 09:10 PM |
| TARNOW MICHAEL M | Director | Jun 21, 2018 | Option Exercise | $3.43 | 12,345 | 42,354 | 67,512 | Jun 22, 2018, 04:40 PM |
| AZAB MOHAMMAD | Director | Jun 21, 2018 | Option Exercise | $3.70 | 10,288 | 38,066 | 54,498 | Jun 22, 2018, 04:39 PM |
| PATOU GARY | Director | Jun 14, 2018 | Option Exercise | $8.30 | 2,856 | 23,705 | 17,402 | Jun 15, 2018, 07:32 PM |
| PATOU GARY | Director | Jun 14, 2018 | Option Exercise | $3.70 | 8,230 | 30,451 | 20,258 | Jun 15, 2018, 07:32 PM |
| ROBIN SHERRINGTON | EVP Bus. & Corp. Development | Mar 15, 2018 | Option Exercise | $4.63 | 1,928 | 8,917 | 5,892 | Mar 16, 2018, 04:33 PM |
| ROBIN SHERRINGTON | EVP Bus. & Corp. Development | Mar 15, 2018 | Option Exercise | $3.77 | 3,086 | 11,634 | 7,820 | Mar 16, 2018, 04:33 PM |
| HOLLER FRANK A | Director | Mar 14, 2018 | Option Exercise | $3.77 | 3,086 | 11,634 | 118,955 | Mar 16, 2018, 04:23 PM |
| PIMSTONE SIMON N. | CEO | Mar 12, 2018 | Option Exercise | $3.77 | 10,288 | 38,786 | 228,135 | Mar 14, 2018, 04:52 PM |
| COHEN CHARLES J. | VP, Biology | Feb 12, 2018 | Option Exercise | $3.50 | 22,669 | 79,342 | 4,079 | Feb 14, 2018, 05:55 PM |
| COHEN CHARLES J. | VP, Biology | Feb 12, 2018 | Option Exercise | $3.71 | 26,748 | 99,235 | 26,748 | Feb 14, 2018, 05:55 PM |
| AZAB MOHAMMAD | Director | Nov 15, 2017 | Buy | $2.22 | 15,000 | 33,280 | 44,210 | Nov 16, 2017, 04:56 PM |
| AZAB MOHAMMAD | Director | Sep 22, 2017 | Buy | $2.95 | 8,000 | 23,600 | 29,210 | Sep 25, 2017, 05:00 PM |
| AZAB MOHAMMAD | Director | Sep 21, 2017 | Buy | $2.95 | 2,000 | 5,900 | 21,210 | Sep 25, 2017, 05:00 PM |
| AZAB MOHAMMAD | Director | Aug 18, 2017 | Buy | $2.90 | 6,312 | 18,302 | 19,210 | Aug 21, 2017, 04:49 PM |
| AZAB MOHAMMAD | Director | Aug 17, 2017 | Buy | $2.65 | 23 | 61 | 12,898 | Aug 21, 2017, 04:49 PM |
| WINQUIST RAYMOND | Head, Translational Research | Aug 18, 2017 | Buy | $2.99 | 1,000 | 2,995 | 1,000 | Aug 21, 2017, 04:48 PM |
| EMPFIELD JAMES R. | SVP, Drug Discovery | Aug 15, 2017 | Buy | $2.48 | 10,000 | 24,824 | 10,000 | Aug 17, 2017, 05:33 PM |
| BVF PARTNERS L P/IL | 10% Owner | Aug 14, 2017 | Buy | $2.70 | 41,344 | 111,778 | 1,663,039 | Aug 16, 2017, 06:55 PM |
| BVF PARTNERS L P/IL | 10% Owner | Aug 15, 2017 | Buy | $2.41 | 18,858 | 45,489 | 1,674,468 | Aug 16, 2017, 06:55 PM |
| Svoronos Dawn | Director | Aug 14, 2017 | Buy | $2.82 | 50,000 | 140,770 | 50,000 | Aug 15, 2017, 04:54 PM |
| PATOU GARY | Director | Aug 10, 2017 | Buy | $2.78 | 7,500 | 20,836 | 12,500 | Aug 14, 2017, 06:07 PM |
| MORTIMER IAN | CFO & COO | Aug 10, 2017 | Buy | $2.90 | 10,000 | 29,000 | 14,300 | Aug 14, 2017, 06:07 PM |
| MORTIMER IAN | CFO & COO | Aug 10, 2017 | Buy | $2.85 | 5,000 | 14,225 | 6,000 | Aug 14, 2017, 06:07 PM |
| SCHELLER RICHARD H | Director | Aug 10, 2017 | Buy | $2.85 | 7,000 | 19,950 | 7,000 | Aug 14, 2017, 06:07 PM |
| PIMSTONE SIMON N. | President & CEO | Aug 10, 2017 | Buy | $2.90 | 6,000 | 17,400 | 217,847 | Aug 14, 2017, 06:06 PM |
| Hayden Michael R | Director | Aug 14, 2017 | Buy | $2.75 | 15,000 | 41,247 | 161,187 | Aug 14, 2017, 06:06 PM |
| GANNON STEVEN | Director | Aug 11, 2017 | Buy | $2.82 | 15,000 | 42,267 | 15,000 | Aug 14, 2017, 06:05 PM |
| PATOU GARY | Director | Aug 08, 2017 | Buy | $3.00 | 5,000 | 15,002 | 5,000 | Aug 10, 2017, 07:58 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 27, 2017 | Buy | $3.04 | 85,461 | 259,468 | 1,635,032 | Jun 30, 2017, 12:00 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 27, 2017 | Buy | $4.00 | 85,461 | 341,844 | 1,635,032 | Jun 29, 2017, 06:21 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 22, 2017 | Buy | $4.00 | 8,263 | 33,052 | 1,588,237 | Jun 23, 2017, 07:16 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 21, 2017 | Buy | $4.00 | 12,148 | 48,592 | 1,583,712 | Jun 23, 2017, 07:16 PM |
| TARNOW MICHAEL M | Director | Jun 19, 2017 | Option Exercise | $3.51 | 1,028 | 3,608 | 56,195 | Jun 20, 2017, 04:37 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 19, 2017 | Buy | $3.85 | 3,595 | 13,841 | 1,577,332 | Jun 19, 2017, 07:33 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 16, 2017 | Buy | $3.85 | 11,034 | 42,481 | 1,575,365 | Jun 19, 2017, 07:33 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 15, 2017 | Buy | $3.84 | 11,779 | 45,196 | 1,569,268 | Jun 19, 2017, 07:33 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 07, 2017 | Buy | $3.85 | 207,789 | 800,237 | 1,562,494 | Jun 08, 2017, 06:58 PM |
| BVF PARTNERS L P/IL | 10% Owner | Jun 06, 2017 | Buy | $3.75 | 150,909 | 565,909 | 1,449,048 | Jun 08, 2017, 06:58 PM |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | May 12, 2017 | Option Exercise | $4.18 | 1,345 | 5,622 | 4,734 | May 16, 2017, 04:32 PM |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | May 12, 2017 | Option Exercise | $3.21 | 2,057 | 6,603 | 6,079 | May 16, 2017, 04:32 PM |
| Hayden Michael R | Director | Mar 14, 2017 | Option Exercise | $3.44 | 11,830 | 40,711 | 30,348 | Mar 15, 2017, 07:53 PM |
| Hayden Michael R | Director | Mar 14, 2017 | Option Exercise | $3.73 | 48,868 | 182,200 | 146,187 | Mar 15, 2017, 07:53 PM |
| HOLLER FRANK A | Director | Dec 15, 2016 | Sale | $7.85 | 30,000 | 235,500 | 115,869 | Dec 19, 2016, 05:07 PM |
| TARNOW MICHAEL M | Director | Dec 12, 2016 | Option Exercise | $3.21 | 14,403 | 46,234 | 69,570 | Dec 13, 2016, 04:57 PM |
| PATOU GARY | Director | Dec 06, 2016 | Option Exercise | $7.90 | 4,403 | 34,784 | 12,028 | Dec 08, 2016, 04:52 PM |
| PATOU GARY | Director | Dec 06, 2016 | Option Exercise | $3.21 | 12,345 | 39,627 | 16,431 | Dec 08, 2016, 04:52 PM |
| AZAB MOHAMMAD | Director | Dec 01, 2016 | Option Exercise | $7.80 | 4,408 | 34,382 | 12,875 | Dec 02, 2016, 06:05 PM |
| AZAB MOHAMMAD | Director | Dec 01, 2016 | Option Exercise | $3.21 | 12,345 | 39,627 | 17,283 | Dec 02, 2016, 06:05 PM |
| HOLLER FRANK A | Director | Aug 19, 2016 | Sale | $7.65 | 11,938 | 91,338 | 145,869 | Aug 23, 2016, 04:51 PM |
| HOLLER FRANK A | Director | Aug 18, 2016 | Sale | $7.70 | 9,599 | 73,912 | 157,807 | Aug 18, 2016, 08:24 PM |
| HOLLER FRANK A | Director | Aug 17, 2016 | Sale | $7.89 | 1,600 | 12,624 | 167,406 | Aug 18, 2016, 08:24 PM |
| HOLLER FRANK A | Director | Aug 16, 2016 | Sale | $8.25 | 6,863 | 56,620 | 169,006 | Aug 18, 2016, 08:24 PM |
| PIMSTONE SIMON N. | President & CEO | Jul 29, 2016 | Option Exercise | $7.46 | 4,703 | 35,084 | 211,847 | Aug 02, 2016, 05:10 PM |
| PIMSTONE SIMON N. | President & CEO | Jul 29, 2016 | Option Exercise | $3.30 | 12,345 | 40,738 | 216,550 | Aug 02, 2016, 05:10 PM |
| MORTIMER IAN | CFO & COO | Jun 24, 2016 | Buy | $6.15 | 1,000 | 6,150 | 1,000 | Jun 28, 2016, 04:41 PM |
| MORTIMER IAN | CFO & COO | Jun 24, 2016 | Buy | $6.23 | 4,300 | 26,790 | 4,300 | Jun 28, 2016, 04:41 PM |
| Hayden Michael R | Director | May 25, 2016 | Option Exercise | $3.30 | 8,230 | 27,159 | 18,518 | May 27, 2016, 05:07 PM |
| TARNOW MICHAEL M | Director | Apr 28, 2016 | Option Exercise | $3.35 | 1,543 | 5,169 | 56,710 | Apr 29, 2016, 06:12 PM |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Dec 16, 2015 | Option Exercise | $7.94 | 229 | 1,818 | 4,022 | Dec 21, 2015, 06:06 AM |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Dec 16, 2015 | Option Exercise | $5.22 | 411 | 2,145 | 4,251 | Dec 21, 2015, 06:06 AM |
| AZAB MOHAMMAD | Director | Dec 11, 2015 | Option Exercise | $5.22 | 2,469 | 12,888 | 4,938 | Dec 14, 2015, 05:37 PM |
| HOLLER FRANK A | Director | Nov 24, 2015 | Option Exercise | $9.39 | 995 | 9,343 | 175,869 | Nov 25, 2015, 03:50 PM |
| HOLLER FRANK A | Director | Nov 24, 2015 | Option Exercise | $5.22 | 2,057 | 10,738 | 176,864 | Nov 25, 2015, 03:50 PM |
| PATOU GARY | Director | Nov 04, 2015 | Option Exercise | $8.32 | 1,955 | 16,266 | 4,086 | Nov 06, 2015, 05:20 PM |
| PATOU GARY | Director | Nov 04, 2015 | Option Exercise | $5.22 | 3,497 | 18,254 | 6,041 | Nov 06, 2015, 05:20 PM |
| TARNOW MICHAEL M | Director | Nov 02, 2015 | Option Exercise | $5.22 | 5,041 | 26,314 | 60,208 | Nov 04, 2015, 06:43 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Sep 22, 2015 | Option Exercise | $9.53 | 8,342 | 79,499 | 28,149 | Sep 24, 2015, 09:56 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Sep 22, 2015 | Option Exercise | $3.24 | 30,388 | 98,513 | 29,218 | Sep 24, 2015, 09:56 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Sep 23, 2015 | Sale | $9.02 | 4,000 | 36,080 | 18,000 | Sep 24, 2015, 09:56 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Sep 22, 2015 | Sale | $9.33 | 6,149 | 57,384 | 22,000 | Sep 24, 2015, 09:56 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Sep 24, 2015 | Sale | $8.60 | 12,000 | 103,200 | 6,000 | Sep 24, 2015, 09:56 PM |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Aug 18, 2015 | Option Exercise | $11.00 | 1,302 | 14,322 | 3,840 | Aug 20, 2015, 01:13 PM |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | Aug 18, 2015 | Option Exercise | $4.92 | 3,085 | 15,189 | 4,708 | Aug 20, 2015, 01:13 PM |
| PIMSTONE SIMON N. | President & CEO | Aug 18, 2015 | Option Exercise | $11.00 | 8,678 | 95,458 | 204,205 | Aug 20, 2015, 01:11 PM |
| PIMSTONE SIMON N. | President & CEO | Aug 18, 2015 | Option Exercise | $4.94 | 20,576 | 101,594 | 210,713 | Aug 20, 2015, 01:11 PM |
| HOLLER FRANK A | Director | Aug 18, 2015 | Option Exercise | $11.00 | 868 | 9,548 | 174,807 | Aug 20, 2015, 01:08 PM |
| HOLLER FRANK A | Director | Aug 18, 2015 | Option Exercise | $4.98 | 2,057 | 10,244 | 175,675 | Aug 20, 2015, 01:08 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Aug 18, 2015 | Option Exercise | $11.00 | 1,302 | 14,322 | 6,103 | Aug 20, 2015, 01:04 PM |
| GOLDBERG Y. PAUL | VP of Clinical Development | Aug 18, 2015 | Option Exercise | $4.92 | 3,085 | 15,189 | 6,971 | Aug 20, 2015, 01:04 PM |
| TARNOW MICHAEL M | Director | Jun 17, 2015 | Option Exercise | $4.95 | 1,543 | 7,638 | 55,167 | Jun 19, 2015, 04:31 PM |
| Hayden Michael R | Director | Feb 03, 2015 | Option Exercise | $4.81 | 5,144 | 24,743 | 10,288 | Feb 05, 2015, 06:09 PM |
| PATOU GARY | Director | Jan 07, 2015 | Option Exercise | $22.28 | 953 | 21,233 | 2,544 | Jan 21, 2015, 08:13 PM |
| PATOU GARY | Director | Jan 07, 2015 | Option Exercise | $4.98 | 3,497 | 17,415 | 3,497 | Jan 21, 2015, 08:13 PM |
| TARNOW MICHAEL M | Director | Jan 08, 2015 | Option Exercise | $4.98 | 5,041 | 25,104 | 53,624 | Jan 12, 2015, 07:08 PM |
| Hayden Michael R | Director | Jan 08, 2015 | Option Exercise | $4.98 | 5,144 | 25,617 | 5,144 | Jan 12, 2015, 07:06 PM |
| AZAB MOHAMMAD | Director | Jan 08, 2015 | Option Exercise | $4.98 | 2,469 | 12,296 | 2,469 | Jan 12, 2015, 07:04 PM |
| PATOU GARY | Director | Jan 07, 2015 | Option Exercise | $4.98 | 3,497 | 17,415 | 3,497 | Jan 09, 2015, 08:30 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| GAROFALO ELIZABETH A. | Director | 03/08/2024 | 64,993 |
| GAROFALO ELIZABETH A. | Director | 03/08/2024 | 64,960 |
| GAROFALO ELIZABETH A. | Director | 03/08/2024 | 95,583 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/07/2024 | 69,124 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/07/2024 | 85,114 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/07/2024 | 330,290 |
| GANNON STEVEN | Director | 03/07/2024 | 601,615 |
| AZAB MOHAMMAD | Director | 12/19/2023 | 42,552 |
| PATOU GARY | Director | 12/14/2023 | 311,898 |
| PATOU GARY | Director | 12/13/2023 | 119,913 |
| PATOU GARY | Director | 12/13/2023 | 137,487 |
| PATOU GARY | Director | 12/13/2023 | 311,898 |
| PATOU GARY | Director | 12/13/2023 | 447,085 |
| Svoronos Dawn | Director | 08/24/2023 | 967,500 |
| PIMSTONE SIMON N. | Director | 06/01/2023 | 870,971 |
| PIMSTONE SIMON N. | Director | 05/31/2023 | 1,124,586 |
| PIMSTONE SIMON N. | Director | 05/31/2023 | 1,181,875 |
| PIMSTONE SIMON N. | Director | 06/01/2023 | 870,855 |
| PIMSTONE SIMON N. | Director | 05/31/2023 | 2,420,051 |
| PIMSTONE SIMON N. | Director | 05/30/2023 | 1,453,672 |
| PIMSTONE SIMON N. | Director | 06/01/2023 | 1,231,247 |
| MORTIMER IAN | PRESIDENT & CEO | 05/24/2023 | 518,105 |
| MORTIMER IAN | PRESIDENT & CEO | 05/24/2023 | 665,536 |
| MORTIMER IAN | PRESIDENT & CEO | 05/24/2023 | 1,310,931 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 03/24/2023 | 24,507 |
| PIMSTONE SIMON N. | Director | 03/07/2023 | 140,277 |
| PIMSTONE SIMON N. | Director | 03/07/2023 | 190,225 |
| PIMSTONE SIMON N. | Director | 03/07/2023 | 711,199 |
| AZAB MOHAMMAD | Director | 12/12/2022 | 8,270 |
| PATOU GARY | Director | 11/25/2022 | 4,124 |
| PATOU GARY | Director | 11/25/2022 | 5,513 |
| PATOU GARY | Director | 11/23/2022 | 70,610 |
| PATOU GARY | Director | 11/25/2022 | 67,390 |
| AULIN SHERRY | Chief Financial Officer | 09/02/2022 | 130,172 |
| AULIN SHERRY | Chief Financial Officer | 09/02/2022 | 130,061 |
| AULIN SHERRY | Chief Financial Officer | 09/02/2022 | 607,597 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/01/2022 | 237,556 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 08/31/2022 | 59,516 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/01/2022 | 237,500 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 08/31/2022 | 70,443 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 08/31/2022 | 823,547 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/01/2022 | 1,675,476 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 08/12/2022 | 275,911 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 08/12/2022 | 275,750 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 08/12/2022 | 2,211,979 |
| PIMSTONE SIMON N. | Director | 08/16/2022 | 2,004,901 |
| PIMSTONE SIMON N. | Director | 08/15/2022 | 1,281,650 |
| PIMSTONE SIMON N. | Director | 08/12/2022 | 3,488,598 |
| PIMSTONE SIMON N. | Director | 03/08/2022 | 77,000 |
| PIMSTONE SIMON N. | Director | 03/07/2022 | 60,158 |
| PIMSTONE SIMON N. | Director | 03/04/2022 | 30,257 |
| PIMSTONE SIMON N. | Director | 03/07/2022 | 75,514 |
| PIMSTONE SIMON N. | Director | 03/04/2022 | 37,757 |
| PIMSTONE SIMON N. | Director | 03/07/2022 | 948,260 |
| PIMSTONE SIMON N. | Director | 03/04/2022 | 285,425 |
| PIMSTONE SIMON N. | Director | 03/08/2022 | 375,636 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/04/2022 | 21,868 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/04/2022 | 27,180 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 03/04/2022 | 662,208 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 03/04/2022 | 210,043 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 03/07/2022 | 291,629 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 03/04/2022 | 210,000 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 03/07/2022 | 291,400 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 03/07/2022 | 1,003,475 |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 03/04/2022 | 563,919 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 01/21/2022 | 20,167 |
| AZAB MOHAMMAD | Director | 12/15/2021 | 11,326 |
| PATOU GARY | Director | 12/08/2021 | 7,549 |
| Von Seggern Christopher | Chief Commercial Officer | 12/06/2021 | 97,600 |
| PIMSTONE SIMON N. | Director | 11/15/2021 | 550,061 |
| PATOU GARY | Director | 03/17/2021 | 1,949 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 05/28/2021 | 79,725 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 05/28/2021 | 97,907 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 05/28/2021 | 114,120 |
| PIMSTONE SIMON N. | CEO | 05/24/2021 | 97,307 |
| PIMSTONE SIMON N. | CEO | 05/24/2021 | 85,100 |
| Hayden Michael R | Director | 02/16/2021 | 13,786 |
| Hayden Michael R | Director | 02/18/2021 | 120,472 |
| AZAB MOHAMMAD | Director | 12/15/2020 | 11,603 |
| TARNOW MICHAEL M | Director | 10/28/2020 | 38,683 |
| PATOU GARY | Director | 10/28/2020 | 7,734 |
| TARNOW MICHAEL M | Director | 06/09/2020 | 18,107 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 06/01/2020 | 22,331 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 06/01/2020 | 29,299 |
| HOLLER FRANK A | Director | 05/29/2020 | 10,986 |
| PIMSTONE SIMON N. | CEO | 06/01/2020 | 43,290 |
| PIMSTONE SIMON N. | CEO | 05/29/2020 | 69,950 |
| PIMSTONE SIMON N. | CEO | 05/26/2020 | 16,509 |
| PIMSTONE SIMON N. | CEO | 05/26/2020 | 21,972 |
| AZAB MOHAMMAD | Director | 12/16/2019 | 10,986 |
| PATOU GARY | Director | 12/04/2019 | 7,323 |
| TARNOW MICHAEL M | Director | 11/21/2019 | 25,533 |
| PIMSTONE SIMON N. | CEO | 09/20/2019 | 98,856 |
| HOLLER FRANK A | Director | 09/20/2019 | 48,884 |
| HOLLER FRANK A | Director | 09/19/2019 | 70,452 |
| PIMSTONE SIMON N. | CEO | 09/17/2019 | 162,651 |
| PIMSTONE SIMON N. | CEO | 09/17/2019 | 203,381 |
| HOLLER FRANK A | Director | 09/18/2019 | 40,535 |
| HOLLER FRANK A | Director | 09/17/2019 | 47,243 |
| AZAB MOHAMMAD | Director | 09/13/2019 | 214 |
| HOLLER FRANK A | Director | 09/12/2019 | 90,508 |
| HOLLER FRANK A | Director | 09/12/2019 | 98,052 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/12/2019 | 17,522 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 09/12/2019 | 18,948 |
| TARNOW MICHAEL M | Director | 05/21/2019 | 6,603 |
| Hayden Michael R | Director | 03/19/2019 | 69,547 |
| PATOU GARY | Director | 12/14/2018 | 6,315 |
| COHEN CHARLES J. | VP, Biology | 12/11/2018 | 11,508 |
| COHEN CHARLES J. | VP, Biology | 12/11/2018 | 12,633 |
| AZAB MOHAMMAD | Director | 12/06/2018 | 9,474 |
| TARNOW MICHAEL M | Director | 06/21/2018 | 42,354 |
| AZAB MOHAMMAD | Director | 06/21/2018 | 38,066 |
| PATOU GARY | Director | 06/14/2018 | 23,705 |
| PATOU GARY | Director | 06/14/2018 | 30,451 |
| ROBIN SHERRINGTON | EVP Bus. & Corp. Development | 03/15/2018 | 8,917 |
| ROBIN SHERRINGTON | EVP Bus. & Corp. Development | 03/15/2018 | 11,634 |
| HOLLER FRANK A | Director | 03/14/2018 | 11,634 |
| PIMSTONE SIMON N. | CEO | 03/12/2018 | 38,786 |
| COHEN CHARLES J. | VP, Biology | 02/12/2018 | 79,342 |
| COHEN CHARLES J. | VP, Biology | 02/12/2018 | 99,235 |
| AZAB MOHAMMAD | Director | 11/15/2017 | 33,280 |
| AZAB MOHAMMAD | Director | 09/22/2017 | 23,600 |
| AZAB MOHAMMAD | Director | 09/21/2017 | 5,900 |
| AZAB MOHAMMAD | Director | 08/18/2017 | 18,302 |
| AZAB MOHAMMAD | Director | 08/17/2017 | 61 |
| WINQUIST RAYMOND | Head, Translational Research | 08/18/2017 | 2,995 |
| EMPFIELD JAMES R. | SVP, Drug Discovery | 08/15/2017 | 24,824 |
| BVF PARTNERS L P/IL | 10% Owner | 08/14/2017 | 111,778 |
| BVF PARTNERS L P/IL | 10% Owner | 08/15/2017 | 45,489 |
| Svoronos Dawn | Director | 08/14/2017 | 140,770 |
| PATOU GARY | Director | 08/10/2017 | 20,836 |
| MORTIMER IAN | CFO & COO | 08/10/2017 | 29,000 |
| MORTIMER IAN | CFO & COO | 08/10/2017 | 14,225 |
| SCHELLER RICHARD H | Director | 08/10/2017 | 19,950 |
| PIMSTONE SIMON N. | President & CEO | 08/10/2017 | 17,400 |
| Hayden Michael R | Director | 08/14/2017 | 41,247 |
| GANNON STEVEN | Director | 08/11/2017 | 42,267 |
| PATOU GARY | Director | 08/08/2017 | 15,002 |
| BVF PARTNERS L P/IL | 10% Owner | 06/27/2017 | 259,468 |
| BVF PARTNERS L P/IL | 10% Owner | 06/27/2017 | 341,844 |
| BVF PARTNERS L P/IL | 10% Owner | 06/22/2017 | 33,052 |
| BVF PARTNERS L P/IL | 10% Owner | 06/21/2017 | 48,592 |
| TARNOW MICHAEL M | Director | 06/19/2017 | 3,608 |
| BVF PARTNERS L P/IL | 10% Owner | 06/19/2017 | 13,841 |
| BVF PARTNERS L P/IL | 10% Owner | 06/16/2017 | 42,481 |
| BVF PARTNERS L P/IL | 10% Owner | 06/15/2017 | 45,196 |
| BVF PARTNERS L P/IL | 10% Owner | 06/07/2017 | 800,237 |
| BVF PARTNERS L P/IL | 10% Owner | 06/06/2017 | 565,909 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 05/12/2017 | 5,622 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 05/12/2017 | 6,603 |
| Hayden Michael R | Director | 03/14/2017 | 40,711 |
| Hayden Michael R | Director | 03/14/2017 | 182,200 |
| HOLLER FRANK A | Director | 12/15/2016 | 235,500 |
| TARNOW MICHAEL M | Director | 12/12/2016 | 46,234 |
| PATOU GARY | Director | 12/06/2016 | 34,784 |
| PATOU GARY | Director | 12/06/2016 | 39,627 |
| AZAB MOHAMMAD | Director | 12/01/2016 | 34,382 |
| AZAB MOHAMMAD | Director | 12/01/2016 | 39,627 |
| HOLLER FRANK A | Director | 08/19/2016 | 91,338 |
| HOLLER FRANK A | Director | 08/18/2016 | 73,912 |
| HOLLER FRANK A | Director | 08/17/2016 | 12,624 |
| HOLLER FRANK A | Director | 08/16/2016 | 56,620 |
| PIMSTONE SIMON N. | President & CEO | 07/29/2016 | 35,084 |
| PIMSTONE SIMON N. | President & CEO | 07/29/2016 | 40,738 |
| MORTIMER IAN | CFO & COO | 06/24/2016 | 6,150 |
| MORTIMER IAN | CFO & COO | 06/24/2016 | 26,790 |
| Hayden Michael R | Director | 05/25/2016 | 27,159 |
| TARNOW MICHAEL M | Director | 04/28/2016 | 5,169 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 12/16/2015 | 1,818 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 12/16/2015 | 2,145 |
| AZAB MOHAMMAD | Director | 12/11/2015 | 12,888 |
| HOLLER FRANK A | Director | 11/24/2015 | 9,343 |
| HOLLER FRANK A | Director | 11/24/2015 | 10,738 |
| PATOU GARY | Director | 11/04/2015 | 16,266 |
| PATOU GARY | Director | 11/04/2015 | 18,254 |
| TARNOW MICHAEL M | Director | 11/02/2015 | 26,314 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 09/22/2015 | 79,499 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 09/22/2015 | 98,513 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 09/23/2015 | 36,080 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 09/22/2015 | 57,384 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 09/24/2015 | 103,200 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 08/18/2015 | 14,322 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 08/18/2015 | 15,189 |
| PIMSTONE SIMON N. | President & CEO | 08/18/2015 | 95,458 |
| PIMSTONE SIMON N. | President & CEO | 08/18/2015 | 101,594 |
| HOLLER FRANK A | Director | 08/18/2015 | 9,548 |
| HOLLER FRANK A | Director | 08/18/2015 | 10,244 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 08/18/2015 | 14,322 |
| GOLDBERG Y. PAUL | VP of Clinical Development | 08/18/2015 | 15,189 |
| TARNOW MICHAEL M | Director | 06/17/2015 | 7,638 |
| Hayden Michael R | Director | 02/03/2015 | 24,743 |
| PATOU GARY | Director | 01/07/2015 | 21,233 |
| PATOU GARY | Director | 01/07/2015 | 17,415 |
| TARNOW MICHAEL M | Director | 01/08/2015 | 25,104 |
| Hayden Michael R | Director | 01/08/2015 | 25,617 |
| AZAB MOHAMMAD | Director | 01/08/2015 | 12,296 |
| PATOU GARY | Director | 01/07/2015 | 17,415 |
Load More Insider Transactions
FUNDS WITH A POSITION IN XENON PHARMACEUTICALS INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,419,472 | 1.67% | 2.26% | Growth |
| CAPITAL WORLD INVESTORS | 2,681,537 | 0.02% | No change | Growth At A Reasonable Price |
| BLACKROCK INC. | 2,095,894 | 0.00185% | -1.23% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,839,555 | 0.13% | 10.03% | Other |
| BAKER BROS. ADVISORS LP | 993,679 | 0.5% | No change | Other |
| ORBIMED ADVISORS LLC | 862,362 | 0.66% | 56.79% | Other |
| CANDRIAM S.C.A. | 521,836 | 0.12% | -6.96% | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 233,335 | 0.02% | 15.93% | Event Driven |
| D. E. SHAW & CO., INC. | 161,722 | 0.0059% | -18.54% | Other |
| BAMCO INC /NY/ | 100,100 | 0.01% | No change | Growth At A Reasonable Price |
| RENAISSANCE TECHNOLOGIES LLC | 92,900 | 0.00614% | 64.72% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 68,929 | 0.00024% | 7.32% | Other |
| ALPS ADVISORS INC | 58,853 | 0.02% | 10.63% | Other |
| TUDOR INVESTMENT CORP ET AL | 25,232 | 0.00504% | 0.3% | Event Driven, Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 7,987 | 0.02% | Exited | Value |
CHANGE IN SHARES OUTSTANDING FOR XENON PHARMACEUTICALS INC.
STOCK BUYBACKS FOR XENON PHARMACEUTICALS INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 06/30/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2024
0.10%
1Q
12/31/2023
11.01%
2Q
09/30/2023
17.68%
3Q
06/30/2023
17.93%
4Q
03/31/2023
18.18%
5Q
12/31/2022
18.30%
6Q
09/30/2022
18.65%
7Q
06/30/2022
38.22%
8Q
03/31/2022
41.60%
9Q
12/31/2021
78.03%
10Q
09/30/2021
83.73%
11Q
06/30/2021
84.53%
12Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR XENON PHARMACEUTICALS INC.
LOADING...